These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 311514)

  • 1. [Immune profile in patients with Hodgkin's disease in long-term remission after cytostatic chemotherapy].
    Nagel GA; Pietra CD; Hartmann D; Rosenthal M; Albrecht R; Obrist R; Obrecht P
    Schweiz Med Wochenschr; 1979 Jan; 109(2):45-51. PubMed ID: 311514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persisting lymphocyte deficiences during remission in Hodgkin's disease.
    Björkholm M; Holm G; Mellstedt H
    Clin Exp Immunol; 1977 Jun; 28(3):389-93. PubMed ID: 302164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Pathol Biol (Paris); 1978; 26(3-4):159-62. PubMed ID: 355984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Sem Hop; 1978 Nov 8-15; 54(37-40):1155-8. PubMed ID: 217096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological study of patients with Hodgkin's disease in long-lasting not-maintained complete remission.
    Gobbi M; Fiacchini M; Tomasini I; Ruggero D; Lauria F; Tura S
    Boll Ist Sieroter Milan; 1977 Mar; 56(2):144-51. PubMed ID: 326273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative study of T and B lymphocytes in Hodgkin's disease.
    Bensa JC; Micouin C; Schaerer R; Sotto JJ; Hollard D
    Biomedicine; 1977 Apr; 26(2):137-44. PubMed ID: 326312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunological data in the clinical evaluation of Hodgkin's diseases].
    Burchardt K
    Z Gesamte Inn Med; 1981 Nov; 36(21):840. PubMed ID: 6977241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levamisole in the treatment of Hodgkin's disease.
    Berényi E; Kávai M; Szabolcsi M; Szegedi G
    Acta Med Acad Sci Hung; 1979; 36(2):177-85. PubMed ID: 317549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
    J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [T- and B-lymphocyte changes in lymphogranulomatosis].
    Il'in NV; Vinokurova NA; Gershanovich ML; Letskiĭ VB
    Vopr Onkol; 1979; 25(6):19-22. PubMed ID: 380155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proportions and absolute count of T- and B-lymphocytes in peripheral blood and their blastic transformation induced by mitogens in splenectomized and non-splenectomized patients with Hodgkin's disease].
    Pluzańska A
    Acta Haematol Pol; 1978; 9(1):37-44. PubMed ID: 307325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect.
    Björkholm M; Holm G; Mellstedt H; Johansson B; Killander D; Sunblad R; Söderberg G
    Scand J Haematol; 1978 Apr; 20(4):306-18. PubMed ID: 653310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B and T lymphocytes in Hodgkin's disease. Analysis at diagnosis and following therapy.
    Gajl-Peczalska KJ; Bloomfield CD; Sosin H; Kersey JH
    Clin Exp Immunol; 1976 Jan; 23(1):47-55. PubMed ID: 1083318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of immunocompetence in Hodgkin's disease.
    Faguet GB
    J Clin Invest; 1975 Oct; 56(4):951-7. PubMed ID: 1159096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of cytotoxic Hodgkin's serum on LIF activity of T- and B-lymphocytes].
    Chisesi T; Giacobbo M; Capnist T
    Boll Ist Sieroter Milan; 1978 Sep; 57(4):428-33. PubMed ID: 310684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune condition in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Traczyk Z; Pawelski S; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Karpowicz M; Małkowska-Zwierz W
    Arch Immunol Ther Exp (Warsz); 1980; 28(1):153-60. PubMed ID: 6968189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal natural killer cell activity in Hodgkin's disease patients in remission.
    Douer D; Shaked N; Ramot B
    Clin Exp Immunol; 1987 Sep; 69(3):660-7. PubMed ID: 3665188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of advanced Hodgkin's disease in remission.
    Klener P; Hausner P; Donner L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):213-7. PubMed ID: 6179821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
    Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
    Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hodgkin's disease--an atypical immune reaction].
    Trepel F; Schick P
    Med Klin; 1977 Jun; 72(23):1003-18. PubMed ID: 327241
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.